Amgen’s MariTide Patients Maintain Weight Loss for Two Years

Amgen Inc.’s experimental drug MariTide helped patients maintain weight loss for two years, a positive development for the company that is trying to establish itself as a competitor in obesity treatment.

Amgen shared topline results from a highly watched phase 2 study of the drug on Monday at the JPMorgan Healthcare Conference, but did not release any data.